# LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

> **NCT03090659** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nanjing Legend Biotech Co.** · enrollment: 100 (estimated)

## Conditions studied

- Refractory or Relapsed Multiple Myeloma

## Interventions

- **BIOLOGICAL:** LCAR-B38M CAR-T cell injection

## Key facts

- **NCT ID:** NCT03090659
- **Lead sponsor:** Nanjing Legend Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10-02
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-06-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03090659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03090659, "LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03090659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*